Randomization and intervention
The inclusion and exclusion criteria of the research were previously stated.The current subanalysis involved 383 patients with available data about MDA‐LDL levels both at baseline and at the end of observation at 24 months (febuxostat group, Study flowchart. M, months; MDA‐LDL, malondialdehyde‐modified low‐density lipoprotein.Each participant's baseline treatment, including antidiabetic, antiplatelet, antihypertensive, and lipid‐lowering agents, remained unaffected during the study period, if possible, based on the patient's clinical condition.